

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM430905

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
X-CHEM, LLC		10/01/2016	Corporation:
RECEIVING PARTY DATA			
Name:	CLARIANT INTERNATIONAL, LTD.		
Street Address:	ROTHAUSSTRASSE 61		
City:	MUTTENZ		
State/Country:	SWITZERLAND		
Postal Code:	CH-4132		
Entity Type:	Corporation: SWITZERLAND		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87116777	SULFINOX	
CORRESPONDENCE DATA			
Fax Number:	7043317707		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	7043317259		
Email:	PatMgt.US@clariant.com		
Correspondent Name:	Anthony A. Bisulca		
Address Line 1:	4000 Monroe Road		
Address Line 2:	Intellectual Property Department		
Address Line 4:	Charlotte, NORTH CAROLINA 28205		
NAME OF SUBMITTER:	Anthony A. Bisulca		
SIGNATURE:	/anthony a. bisulca/		
DATE SIGNED:	06/12/2017		
Total Attachments: 7			
source=Redacted original TM Assignment_SULFINOX_X-Chem to CIL on 10-01-2016#page1.tif			
source=Redacted original TM Assignment_SULFINOX_X-Chem to CIL on 10-01-2016#page2.tif			
source=Redacted original TM Assignment_SULFINOX_X-Chem to CIL on 10-01-2016#page3.tif			
source=Redacted original TM Assignment_SULFINOX_X-Chem to CIL on 10-01-2016#page4.tif			
source=Redacted original TM Assignment_SULFINOX_X-Chem to CIL on 10-01-2016#page5.tif			

CH \$40.00 87116777

source=Redacted original TM Assignment_SULFINOX_X-Chem to CIL on 10-01-2016#page6.tif

source=Redacted original TM Assignment_SULFINOX_X-Chem to CIL on 10-01-2016#page7.tif

ASSIGNMENT OF TRADEMARKS

THIS ASSIGNMENT OF TRADEMARKS (this “Trademark Assignment”), effective as of October 1, 2016 (the “Effective Date”), is from X-Chem, LLC, a Louisiana limited liability company (“Assignor”), to Clariant International, Ltd., a company organized under the laws of Switzerland (“Assignee”). Assignor and Assignee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

WHEREAS, [REDACTED]

[REDACTED] Assignor was a wholly-owned subsidiary of NCH Corporation, and NCH Corporation has entered into an [REDACTED] Agreement, [REDACTED] with Clariant Corporation, a New York corporation [REDACTED]

WHEREAS, Assignor is the owner of certain rights, titles and interests in and to the trademarks set forth on the schedule attached hereto as **Exhibit A** (the “Trademarks”), including but not limited to the registrations and applications for registration of the Trademarks identified on the schedule attached hereto as **Exhibit B**, and any and all goodwill of the business in connection with which the Trademarks are used and that is symbolized by the Trademarks (the Trademarks, such applications and registrations, and such goodwill, are collectively referred to as the “Intellectual Property”);

WHEREAS, [REDACTED]

[REDACTED] Assignee desires to acquire the Intellectual Property, and Assignor desires to assign its rights in the Intellectual Property to Assignee; and

[REDACTED]

NOW, THEREFORE, for the consideration stated in the Purchase Agreement and other good and valuable consideration, [REDACTED] the receipt and sufficiency of which are hereby acknowledged, Assignor hereby assigns, transfers, and sells to Assignee the entire right, title, and interest of Assignor in and to (i) the Intellectual Property, including the Trademarks, all registrations and applications for the Trademarks and the goodwill of the business with which the Trademarks are used and that is symbolized by the Trademarks, to the extent that such rights and goodwill exist, and all rights of priority in the Intellectual Property in any country as may not or hereafter be granted to it by law, treaty or other international conventions; (ii) any and all legal actions and rights and remedies at law or in equity for past, present and future infringements, misappropriations, or other violations of the Intellectual Property, including the right to sue for, collect, and retain all damages, profits, proceeds, and all other remedies associated therewith; and (iii) any and all income, royalties, damages, and payments now or hereafter due or payable with respect to the Intellectual Property,

for Assignee's own use and enjoyment and for the use and enjoyment of Assignee's successors, assigns, or other legal representatives as fully and entirely as the same would have been held and enjoyed by Assignor if this Trademark Assignment had not been made (together, the "Assigned Rights").

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

* * * * *

IN WITNESS WHEREOF, the undersigned, being duly authorized and acting on behalf of Assignor and Assignee, do hereby execute this Trademark Assignment to take effect on the Effective Date.

ASSIGNOR:

X-CHEM, LLC

BY: 

NAME: Kenneth L. Golder

TITLE: President

[Signature Page to Assignment of Trademarks]

ASSIGNEE:


CLARIANT INTERNATIONAL LTD

BY: 

NAME: Dr. Peter Zimmermann
Corporate Counsel

TITLE: _____

and

BY: 

NAME: Dr. Ute Scherer-Friedhoff

TITLE: Corporate Counsel

[Signature Page to Assignment of Trademarks]

Exhibit A

Trademarks

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

SULFINOX

[REDACTED]

[REDACTED]

Exhibit B

U.S. Trademark Registrations and Applications

<u>MARK</u>	<u>APP. NO.</u>	<u>FILING DATE</u>
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]
SULFINOX	87116777	7/26/2016
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

